Mircod
Mircod is a company specializing in sophisticated electronic design and turnkey development for IoT, IoMT (Healthcare IoT), biotechnology, robotics, and healthcare industries. They provide comprehensive services including circuit schematics, embedded systems, firmware programming, user-interface development, and hardware design compliant with CE, FCE, UL, ROHS, WEEE, and FDA standards. Mircod's expertise enables rapid prototyping and production of hardware and software solutions, supporting R&D projects in gene therapy, IoT platforms, AI-enabled robotics for biotech labs, and advanced remote monitoring technology for healthcare. Their multi-disciplinary team ensures high-quality, scalable product development from concept to market.
Mircod
Mircod is a company specializing in sophisticated electronic design and turnkey development for IoT, IoMT (Healthcare IoT), biotechnology, robotics, and healthcare industries. They provide comprehensive services including circuit schematics, embedded systems, firmware programming, user-interface development, and hardware design compliant with CE, FCE, UL, ROHS, WEEE, and FDA standards. Mircod's expertise enables rapid prototyping and production of hardware and software solutions, supporting R&D projects in gene therapy, IoT platforms, AI-enabled robotics for biotech labs, and advanced remote monitoring technology for healthcare. Their multi-disciplinary team ensures high-quality, scalable product development from concept to market.
TL;DR
Founded: 2015
Headquarters: Boca Raton, Florida, United States
Focus: IoT, IoMT, biotechnology, healthcare hardware & firmware development
Employees: 43
Last known funding: Seed round, Jan 1, 2018
Company Overview
Problem Domain
Bridging hardware, firmware, and regulatory requirements for medical/biotech IoT devices and lab automation.
Founded
2015
Industry
Biotechnology
Tech Stack
Funding Track Record
Most recent seed round listed on Jan 1, 2018; Crunchbase lists three seed rounds in total.
Investor Signal
“Angel investors named (six total investors listed, including Michael Fainshtein and Oded Federbusch)”